Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial

Diabetes Care

Volumn 40, Issue 1, 2017, Pages 69-76

  Mosenzon, Ofri ^a   Leibowitz, Gil ^a   Bhatt, Deepak L ^b   Cahn, Avivit ^a   Hirshberg, Boaz ^c   Wei, Cheryl ^d   Im, Kyung Ah ^b   Rozenberg, Aliza ^a   Yanuv, Ilan ^a   Stahre, Christina ^e   Ray, Kausik K ^f   Iqbal, Nayyar ^d   Braunwald, Eugene ^b   Scirica, Benjamin M ^b   Raz, Itamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MEDIMMUNE   (United States)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; PLACEBO; SAXAGLIPTIN; ADAMANTANE; CREATININE; DIPEPTIDE; GLUCOSE BLOOD LEVEL; SERUM ALBUMIN;

ADULT; AGED; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; KIDNEY TRANSPLANTATION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; MULTICENTER STUDY;

ADAMANTANE; AGED; ALBUMINURIA; BLOOD GLUCOSE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; SERUM ALBUMIN;

EID: 85008230357     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0621     Document Type: Article

References (37)

1. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: A report from an ADA Consensus Conference. Diabetes Care 2014;37: 2864-2883
2. Adler S. Diabetic nephropathy: Linking histology, cell biology, and genetics. Kidney Int 2004; 66:2095-2106
3. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63: 225-232
4. Cravedi P, Ruggenenti P, Remuzzi G. Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 2012;8:301-306
5. Gerstein HC,Mann JF, Yi Q, et al.; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286: 421-426
6. de Zeeuw D, Parving HH, Henning RH.Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006;17: 2100-2105
7. Lea J, Greene T, Hebert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005;165: 947-953
8. Araki S, Haneda M, Koya D, et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 2007;56: 1727-1730
9. Hellemons ME, Persson F, Bakker SJ, et al. Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: A post hoc analysis of the IRMA-2 trial. Diabetes Care 2011; 34:2078-2083
10. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65: 2309-2320
11. Schmieder RE, Schutte R, Schumacher H, et al.; ONTARGET/TRANSCEND investigators. Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. Diabetologia 2014;57: 2019-2029
12. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011;58:69-73
13. Mori H, Okada Y, Arao T, Tanaka Y. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig 2014;5: 313-319
14. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013;36:3460-3468
15. Von EynattenM, Emser A, Cooper ME, et al. Renal safety and outcomes with linagliptin: meta-analysis of individual data for 5466 patients with type 2 diabetes. J Am Soc Nephrol 2012;23:218A
16. Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 2014;85:579-589
17. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
18. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetesmellitus-thrombolysis inmyocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 2011;162:818-825.e6
19. Mosenzon O, Raz I, Scirica BM, et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev 2013;29:417-426
20. Levey AS, Coresh J, Balk E, et al.; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-147
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130:461-470
22. Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: The continuing saga. Diabetes Care 2014;37:867-875
23. Karasik A, Cohen CM, Chodik G, et al. Urinary albumin secretion in type 2 diabetes patients (T2DM) with albuminuria treated with sitagliptin as add-on therapy to metformin: A real world data study [article online], 2014. Available from http://info.e-med.co.il/januet/files/2014/08/Microalbumin-ADA-poster.pdf. Accessed 4 October 2015
24. Tani S, Nagao K, Hirayama A. Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: A pilot study. Am J Cardiovasc Drugs 2013;13:443-450
25. Heerspink HJ, Kröpelin TF, Hoekman J, de Zeeuw D; Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium. Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. J Am Soc Nephrol 2015;26:2055-2064
26. Tonelli M, Muntner P, Lloyd A, et al.; Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study. Lancet 2012;380: 807-814
27. Heerspink HJ, Ninomiya T, Persson F, et al. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. Diabetes Obes Metab 2016;18:169-177
28. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55: 1832-1839
29. Udell JA, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705
30. Solomon SD, Lin J, Solomon CG, et al.; Prevention of Events With ACE Inhibition (PEACE) Investigators. Influence of albuminuria on cardiovascular risk in patientswith stable coronary artery disease. Circulation 2007;116:2687-2693
31. Mega C, De Lemos TE, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011;2011:162092
32. Alter ML, Ott IM, von Websky K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012;36:119-130
33. Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012;340:248-255
34. Hendarto H, Inoguchi T,Maeda Y, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.Metabolism 2012; 61:1422-1434
35. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54:965-978
36. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132: 2131-2157
37. Mima A, Hiraoka-Yamomoto J, Li Q, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCb activation in diabetes. Diabetes 2012;61:2967-2979